VAXXITEK HVT + IBD
serotype 3, live Marek’s disease vector, live vHVT013-69 recombinant virus (and diluent)
About VAXXITEK® HVT + IBD
To prevent mortality and to reduce clinical signs and lesions of infectious bursal disease. The onset of protection is two weeks and the protection extends to nine weeks.
To reduce mortality, clinical signs and lesions of Marek’s disease. The onset of protection is four days. A single vaccination is sufficient to provide protection during the risk period.
Product Key Facts
Indications
Infectious bursal disease and Marek’s disease
Brand names
VAXXITEK® HVT + IBD
Active ingredients
serotype 3, live Marek’s disease vector, live vHVT013-69 recombinant virus (and diluent)